# Mucopolysaccharidosis II FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/mucopolysaccharidosis-ii

> 4 upcoming FDA catalysts in mucopolysaccharidosis II: tividenofusp alfa (DNLI) on June 2027 (primary completion); tividenofusp alfa (DNLI) on Jun to Sep 2027 (topline data readout); tividenofusp alfa (DNLI) on December 2027 (primary completion); tividenofusp alfa (DNLI) on Dec 2027 to Mar 2028 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| August 18, 2025 | [Clemidsogene lanparvovec PDUFA date](https://sec-api.dev/pdufa/clemidsogene-lanparvovec) | RGNX | Mucopolysaccharidosis II | scheduled | "On August 18, 2025, REGENXBIO Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration ("FDA") has extended the Prescription Drug User Fee Act ("PDUFA") date for the Company's Biologics License Application seeking accelerated approval of clemidsogene lanparvovec (RGX-121) for the treatment of Mucopolysaccharidosis II (MPS II), also known as Hunter syndrome." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1590877/000095017025109829/rgnx-20250818.htm)) |
| June 2027 | [Tividenofusp alfa primary completion](https://sec-api.dev/pdufa/tividenofusp-alfa) | DNLI | Mucopolysaccharidosis II | scheduled | "NCT06075537 (An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2, PHASE3; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Denali Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06075537)) |
| Jun to Sep 2027 | [Tividenofusp alfa topline data readout](https://sec-api.dev/pdufa/tividenofusp-alfa) | DNLI | Mucopolysaccharidosis II | scheduled | "NCT06075537 (An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2, PHASE3; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Denali Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06075537)) |
| December 2027 | [Tividenofusp alfa primary completion](https://sec-api.dev/pdufa/tividenofusp-alfa) | DNLI | Mucopolysaccharidosis II | scheduled | "NCT05371613 (A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Denali Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05371613)) |
| Dec 2027 to Mar 2028 | [Tividenofusp alfa topline data readout](https://sec-api.dev/pdufa/tividenofusp-alfa) | DNLI | Mucopolysaccharidosis II | scheduled | "NCT05371613 (A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Denali Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05371613)) |

## Drugs

- [Clemidsogene lanparvovec](https://sec-api.dev/pdufa/clemidsogene-lanparvovec) (RGNX)
- [Tividenofusp alfa](https://sec-api.dev/pdufa/tividenofusp-alfa) (DNLI)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/mucopolysaccharidosis-ii.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Mucopolysaccharidosis II FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/mucopolysaccharidosis-ii

```bibtex
@misc{secapidev_indications_mucopolysaccharidosis_ii_20261116,
  title        = {Mucopolysaccharidosis II FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/mucopolysaccharidosis-ii}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_mucopolysaccharidosis_ii_20261116","title":"Mucopolysaccharidosis II FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/mucopolysaccharidosis-ii","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
